Migraine drug safety in pregnancy under scrutiny: new registry launches
NCT ID NCT06150781
First seen Nov 05, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study is for pregnant women with migraine who have taken the drug AIMOVIG (erenumab-aooe) during pregnancy. Researchers will compare their babies' health, especially birth defects, to babies born to women with migraine who did not take the drug. The goal is to better understand the safety of AIMOVIG when used during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IQVIA Virtual Site
RECRUITINGDurham, North Carolina, 27703, United States
Conditions
Explore the condition pages connected to this study.